Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated

Repurposing Atovaquone as a Therapeutic against Acute Myeloid Leukemia (AML): Combination with Conventional Chemotherapy Is Feasible and Well Tolerated

Survival of pediatric AML remains poor despite maximized myelosuppressive therapy. The <i>pneumocystis jiroveci pneumonia</i> (PJP)-treating medication atovaquone (AQ) suppresses oxidative phosphorylation (OXPHOS) and reduces AML burden in patient-derived xenograft (PDX) mouse models, ma...

Full description

Bibliographic Details
Main Authors: Alexandra McLean Stevens, Eric S. Schafer, Minhua Li, Maci Terrell, Raushan Rashid, Hana Paek, Melanie B. Bernhardt, Allison Weisnicht, Wesley T. Smith, Noah J. Keogh, Michelle C. Alozie, Hailey H. Oviedo, Alan K. Gonzalez, Tamilini Ilangovan, Alicia Mangubat-Medina, Haopei Wang, Eunji Jo, Cara A. Rabik, Claire Bocchini, Susan Hilsenbeck, Zachary T. Ball, Todd M. Cooper, Michele S. Redell
Format: Article
Language:English
Published: MDPI AG 2023-02-01
Series:Cancers
Subjects:
pediatric
oxidative phosphorylation
metabolism
xenograft
patient-derived
oxygen consumption rate
Online Access:https://www.mdpi.com/2072-6694/15/4/1344

Similar Items

Similar Items